GlassScriptPhysician profile
Michael Shane Busman
NPI 1073584504
$10,827.58
in general payments reported to CMS, 2019-2025
50 companies · $1,521 in 2025
The $1,521 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,058 · 2020: $1,214 · 2021: $1,368 · 2022: $1,539 · 2023: $2,253 · 2024: $1,874 · 2025: $1,521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,649.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,648.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,094.31 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $1,074.89 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $730.71 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $655.56 | 2020-2025 | Vraylar, Ubrelvy, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $586.45 | 2019-2025 | Jardiance, Ofev |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $566.93 | 2020-2025 | Caplyta |
| Amgen INC. | $539.05 | 2019-2025 | Otezla, Repatha, Repatha |
| Lilly USA, LLC | $448.89 | 2020-2025 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $434.82 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $408.84 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $367.93 | 2022-2025 | Ingrezza |
| Dexcom, INC. | $351.90 | 2023-2025 | Dexcom G6 Transmitter |
| Allergan, INC. | $328.53 | 2019-2020 | |
| Merz North America, INC. | $274.64 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $261.90 | 2019-2024 | Xarelto |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Busman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.